Obseva announces U.S. FDA acceptance of new drug application for linzagolix
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
This is Enzene Biosciences third biosimilar to be approved
The group now has 320 approvals and has so far filed over 400 ANDAs
Subscribe To Our Newsletter & Stay Updated